Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.45 |
| ▸ | CA1 | P00915 | 11/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058483 | 0.89 | CA1 (0.47) | CA2CA1MAOAMAOBKDM4E | |
| SCHEMBL14973089 | 0.85 | POLB (0.46) | CA2CA1KDM4EKIF11POLB | |
| SCHEMBL14972940 | 0.85 | CA2 (0.47) | CA2CA1MAOAMAOBKDM4E | |
| SCHEMBL10060159 | 0.85 | CA9 (0.46) | CA2CA1KIF11POLB | |
| SCHEMBL10058843 | 0.84 | S1PR1 (0.41) | CA2CA1MEN1KMT2AKIF11 | |
| SCHEMBL14973183 | 0.82 | CA2 (0.49) | CA2CA1MAOAMAOBKDM4E | |
| SCHEMBL14972931 | 0.77 | CA9 (0.48) | CA2CA1MEN1KMT2APOLB | |
| SCHEMBL10060112 | 0.76 | ADRB2 (0.36) | CA2CA1PTGS2 | |
| SCHEMBL10060113 | 0.76 | KIF11 (0.46) | CA2CA1MEN1KMT2AKIF11 | |
| SCHEMBL10058991 | 0.76 | PTGS2 (0.40) | CA2CA1MEN1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2012020820-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | CA2 2244/4885CA1 1915/4885MAOA 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.